Press Releases

June 29, 2022

 

First Patient Enrolled in Phase 3 OPTIMIZE Trial of OCS-01 for Inflammation and Pain following Cataract Surgery

March 2, 2022

 

Oculis Strengthens Pipeline by In-Licensing Neuroprotective Drug Candidate for Glaucoma

February 8, 2022

 

Oculis appoints Dr. Bastian Dehmel as Chief Development Officer

January 5, 2022

 

Oculis appoints Mr. Webb Ding as Global COO and GM China

November 12, 2021

 

Oculis Announces Patient Dosing in its First Phase 3 with OCS-01 for Diabetic Macular Edema (DIAMOND Study)

October 7, 2021

 

Oculis Appoints Dr. Joanne Chang as Global Chief Medical Officer and Opens Hong Kong Office

May 11, 2021

 

Oculis Announces Positive Data from Two Proof-of-Concept Phase 2 Trials with OCS-02, Presented at ARVO 2021

May 04, 2021

 

Oculis Announces an Oversubscribed US$57 million Series C Financing